Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Adult, Obesity-related, Symptomatic Asthma (GATA-3)

Part of paid clinical trials in Nashville, Tennessee.

Sponsor
Vanderbilt University Medical Center
Study ID
NCT05254314
Phase
PHASE2
Status
Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This is a randomized placebo-controlled trial of semaglutide, an FDA-approved therapy for the treatment of type 2 diabetes mellitus and obesity, in adults with symptomatic asthma despite the use of inhaled steroids and with excess body weight. This study will test the central hypothesis that semaglutide will improve asthma control and reduce airway inflammation due to direct effects on the respiratory tract in adult asthma associated with obesity.

Key Dates

Start date
Oct 11, 2022
Status verified
May 2026
Primary completion
Sep 30, 2026
Completion
Dec 31, 2026

Study Design

Enrollment
100 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Study Drug (Semaglutide)
    Semaglutide 2.4mg once weekly
  • Placebo Comparator: Placebo
    Placebo 2.4mg once weekly

Primary Outcome Measure

The efficacy of semaglutide on asthma control questionnaire-7 score in subjects with symptoms, persistent asthma and obesity. [ Time Frame: Baseline to week 12 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Vanderbilt University Medical CenterNashvilleTennessee37203
Katherine Cahill, MD
615-936-1269
Deborah Hunter
615-936-9123
Katherine Cahill, MD (PRINCIPAL_INVESTIGATOR)
Gordon Bernard, MD (SUB_INVESTIGATOR)
Kevin Niswender, MD (SUB_INVESTIGATOR)
Stoke Peebles, MD (SUB_INVESTIGATOR)
Leonard B Bacharier, MD (SUB_INVESTIGATOR)

Find similar trials in Nashville, TN

By condition

Related Studies